Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568
Tokyo, Japan and Cambridge, UK, 3 June 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) today announces that its partner, Neurocrine Biosciences ('Neurocrine') has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034). The US$15 million payment will be fully recognized as revenue in the second quarter of 2025.
Nxera previously announced the initiation of the Phase 3 registrational program of NBI-'568 by Neurocrine in May 2025. The Phase 3 study is a global double-blind, placebo-controlled trial evaluating NBI-'568 in adults with a primary diagnosis of schizophrenia who are experiencing an acute exacerbation or relapse of symptoms. The study is expected to enroll approximately 280 patients. The primary endpoint of the study is a reduction from baseline in the Positive and Negative Syndrome Scale (PANSS). The key secondary endpoint is improvement in the Clinical Global Impression of Severity (CGI-S) scale.
–END–
About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology/neuropsychiatry, metabolic diseases and immunology and inflammation.
Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@Nxera.life
MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statements
This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Diplomatic win for UK hosting US-China trade talks
Sky News understands that the Trump administration approached the UK government to ask if it would host round two of the US-China trade talks. This is a useful 'diplo-win' for the UK. The first round was held in Geneva last month. News of that happening came as a surprise. The Chinese and the Americans were in the midst of a Trump-instigated trade war. President Trump was en route to Saudi Arabia and suddenly we got word of talks in Switzerland. They went surprisingly well. US treasury secretary Scott Bessent and his Chinese counterpart He Lifeng, met face-to-face and agreed to suspend most tariffs for 90 days. But two weeks later, the Trump administration accused Beijing of breaking the agreements reached in Geneva. Beijing threw the blame back at Washington. On Wednesday, Donald Trump and Xi Jinping spoke by phone. The Chinese claimed this call was at the Americans' request. Either way, the consequence was that the talks were back on track. "I just concluded a very good phone call with President Xi of China, discussing some of the intricacies of our recently made, and agreed to, trade deal," President Trump said this week. From that call came the impetus for a second round of talks. A venue was needed. In stepped the UK at short notice. Beyond being geographically convenient, UK government sources suggest that Britain is geopolitically in the right place right now to act as this bridge and facilitator. The UK-China relationship is in the process of a "reset". Other locations, like Brussels or other EU capitals, would have been less workable. Crucially too, for the UK, this is also potentially advantageous as it seeks to get its own UK-US trade agreement, to eliminate or massively reduce tariffs, over the line. Talks on reaching the "implementation phase" have been near-continuous since the announcement last month, but having the American principals in London is a plus. Sideline talks are possible, but even the presence of the US team in the UK is helpful. Read more from Sky News:Man wrongly deported from US to El Salvador has been returned to face criminal chargesMore than 40 'narco-boat' drug smugglers arrested in major police sting For all the chaos that President Trump is causing with his tariffs, he has instigated face-to-face conversations as he seeks resets. Key players are sitting down around tables - yes, to untangle the trade knots which Trump tied, but this whole episode has pulled foes together around the same table; it has forced relationships and maybe mutual understanding. That's useful. And for this next round, between superpowers, the UK is the host. Also useful.
Yahoo
4 hours ago
- Yahoo
Lemonade First Quarter 2025 Earnings: Beats Expectations
Revenue: US$151.2m (up 27% from 1Q 2024). Net loss: US$62.4m (loss widened by 32% from 1Q 2024). US$0.86 loss per share (further deteriorated from US$0.67 loss in 1Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 4.3%. Earnings per share (EPS) also surpassed analyst estimates by 7.5%. Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Insurance industry in the US. Performance of the American Insurance industry. The company's shares are up 4.6% from a week ago. You should always think about risks. Case in point, we've spotted 3 warning signs for Lemonade you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
The Church of Jesus Christ strengthens global effort, doubling initial projections, helping improve the lives of more than 21 million women and children worldwide
SALT LAKE CITY , June 6, 2025 /PRNewswire/ -- As part of its ongoing responsibility to care for those in need, The Church of Jesus Christ of Latter-day Saints is bolstering its global initiative to improve the well-being of women and children. During meetings on Temple Square in Salt Lake City, Utah, on Thursday, June 5, 2025, Relief Society General President Camille N. Johnson told representatives from eight global humanitarian organizations that the Church is donating another US$63.4 million to this worldwide project first announced in 2023. Last year, the Church announced a $55.8 million donation as part of this effort. "Collaboration remains at the heart of this initiative; we create the greatest impact through our united efforts. Together, we look forward to another year of creating healthier futures for women and children and strengthening communities," President Johnson said. During the gathering, representatives shared key results from 2024, highlighting significant progress: 21.2 million children and mothers received vitamins. 1.87 million children were screened for malnutrition and treated if needed. 1.6 million mothers were trained in nutrition best practices. 219,000 pregnant mothers received prenatal care. 141,000 families received seeds, training or now have home gardens with more nutrient-dense foods. 41,000 people were trained in improved hygiene behaviors. 17,000 government health workers were trained to support maternal and newborn care, child nutrition, breastfeeding, and the administration of vitamins. 6,800 people benefited from improved water and sanitation facilities. 159 newborns were resuscitated at birth. 125 health facilities were trained to track clinical cases of malnutrition and provide treatment. The Church has taken a leadership role in convening eight globally recognized nonprofits, and as part of four groups, each focused on projects benefiting women and children. These organizations are: CARE International, Catholic Relief Services (CRS), Helen Keller Intl, iDE, MAP International, Save the Children, The Hunger Project, and Vitamin Angels. The four groups and their areas of focus and objectives are as follows Group 1: Helen Keller Intl, Vitamin Angels, iDEObjective: Increase access to nutritious foods, vitamins, and medications in 12 countries (Bangladesh, Cambodia, Democratic Republic of the Congo, Ghana, Kenya, Mali, Nepal, Nigeria, Philippines, Senegal, Sierra Leone, and Zambia). Group 2: CRS, The Hunger Project, MAP InternationalObjective: Improve maternal newborn care, water, sanitation, and hygiene, and nutrition in Ghana. Group 3: Save the Children, MAP InternationalObjective: Improve maternal newborn care and nutrition in Sierra Leone and Zambia. Group 4: CARE, iDE, MAP InternationalObjective: Improve agriculture and nutrition and upgrade medical clinics in Nepal. "With our global reach, we are uniquely positioned to foster collaboration among these eight organizations. By leveraging our individual strengths and resources, we amplify our collective impact," said Blaine Maxfield, managing director of Welfare and Self-Reliance Services. "What a blessing it is to come together to serve God's children around the world." The announcement of new funding was part of activities, including an expert panel discussion scheduled for later in the day on Thursday, June 5, led by Bishop L. Todd Budge, Second Counselor in the Church's Presiding Bishopric. The panel focused on health and nutrition for women and children. The panelists were President Camille Johnson, Blaine Maxfield, Sharon Eubank (director of Church Humanitarian Services), Sarah Bouchie (CEO of Helen Keller Intl), Ana Céspedes (CEO of Vitamin Angels), Lizz Welch (CEO of iDE), and Abena Amedormey (Ghana country representative for CRS). In 2023, the First Presidency asked the Relief Society to lead this global effort. President Russell M. Nelson has told women that they have a divine endowment to change lives. He said, "I am inspired by your diligence, dynamic leadership, and your ability to see a need and meet it." Members of The Church of Jesus Christ of Latter-day Saints believe in following the Savior's two great commandments: to love God and to love our neighbor. As part of this mandate, we seek to maximize our impact so our efforts bless not only those who receive help but also their families and communities. For more information on the Church's effort to care for those in need, please visit the most recent "Caring for Those in Need" summary. View original content to download multimedia: SOURCE The Church of Jesus Christ of Latter-day Saints Sign in to access your portfolio
